-
Biopharmaceutical Manufacturing Goes Mainstream
With biologics, the maxim is “process is the product,” and suppliers are meeting the technologies demanded by developers with an equal amount of innovation.
PAP-Q2-17-FA-004 -
The Road to Biologics’ Continued Success
In a short period of time, biopharmaceuticals have had a tremendous impact on both the pharma industry and the lives of countless patients.
PAP-Q2-17-EN-001 -
Biologics: Driving Force in Pharma
Biologics actually accounted for six of the top eight drugs by revenues in 2016.
PAP-Q2-17-NO-001 -
Making Real-Time Process Analytical Technology In Biomanufacturing A Reality
Automated, aseptic sampling and analysis is a prerequisite for making real-time Process Analytical Technology (PAT) in biomanufacturing a commercial reality.
PAP-Q2-17-IL-001 -
Disease-In-A-Dish: Leveraging in vitro Human Models to Advance Drug Discovery
A personalized approach to the generation of therapeutics is gaining greater traction not only with medical personnel, but also with the patient.
PAP-Q2-17-CL-006 -
Speeding Development And Reducing Costs With Analytical Quality By Design
Applying Quality by Design (QbD) principles to analytical method development leads to many benefits.
PAP-Q2-17-CL-006 -
Implications of Serialization for the U.S. Pharma Industry
New requirements under the U.S. Drug Supply Chain Security Act (DSCSA) have been set for pharmaceutical manufacturers.
PAP-Q2-17-CL-001 -
Serialization: The First Steps In Sales Unit Traceability and Data Management
While initially driven by regulations, the impacts of serialization will be far-reaching.
PAP-Q2-17-CL-002 -
Supporting the Tech Transfer Continuum for Cell & Gene Therapies
Organizations that can support the continuum of tech transfer projects will be best positioned to meet the expanding needs of the marketplace.
PAP-Q2-17-CL-003 -
Propagating a Full Spectrum of Services for ADC Development and Manufacture
The development and manufacture of antibody-drug conjugates (ADCs) requires expertise in both biological drug substance and API technologies.
PAP-Q2-17-CL-007 -
Moving Quality to the Forefront Brings Measurable Results
Quality initiatives are imperative in the pharmaceutical industry, but not all quality systems are equal.
PAP-Q2-17-CL-008 -
Making Strides: Biologics Push Forward
Biologics are no longer seen as the ‘next big thing’ in drug development; they are now a mainstay in many pipelines.
PAP-Q2-17-FA-001 -
Clinical Trials Find a Device for Growth
Technology developments and a growing population are driving growth in the clinical trials market.
PAP-Q2-17-FA-002 -
The Search for Alternative Delivery Methods Continues
While biologic drugs offer numerous advantages, the need to administer them parenterally is a significant limitation.
PAP-Q2-17-FA-003 -
From Blobs to Hearts: Understanding the 3D Bioprinting Revolution
Additive manufacturing (AM), commonly referred to as ‘3D printing,’ is a revolutionary technology that seems to bleed across disciplines.
PAP-Q2-17-TT-001 -
Optimizing API Production as a True Manufacturing Partner
The required attributes of a good API — namely quality, safety and effectiveness — stem from good manufacturing processes.
PAP-Q2-17-CL-009 -
Small Molecule Injectable Manufacturing: Challenges and Complexities
Despite the growth of biologic drugs, medicines based on small molecules remain important in the treatment of all types of diseases.
PAP-Q2-17-CL-013 -
Building a One-Stop Shop CDMO for Biopharmaceuticals
There are few true one-stop shop organizations providing support to pharma companies developing biosimilars and branded biologics.
PAP-Q2-17-CL-012 -
The People’s Choice: Premeasured Single Dosage Forms
Taking medication as intended is an issue for many patients — single unit packaging is a solution for better FDA and patient compliance.
PAP-Q2-17-CL-014 -
Design of Complex Biopharmaceutical Facilities: Considering Options and Alternatives
The movement of next-generation drug products toward commercialization is driving the need for new and different technologies and facilities.
PAP-Q2-17-CL-011 -
Designing Flexibility for Added Value
Biopharmaceutical facilities today rely on a wide range of equipment and processes that require a high level of flexibility.
PAP-Q2-17-CL-015 -
Fit Biopharmaceutical Facilities: A Predictive Maintenance Approach
It is essential that both mature and newer existing facilities manage the aging process.
PAP-Q2-17-CL-010 -
Nice Symposium Oral Solid Dose 2017: Bringing the Supply Chain Together to Tackle Development Challenges
The first-ever “Nice Symposium,” hosted by That’s Nice, brought together a diverse range of service and technology providers and their customers.
PAP-Q2-17-NS-001 -
Q: If You Could Have One Piece of Biologic Manufacturing Equipment Improved, What Would It Be and Why?
Improving bioreactor and cell retention setup used in perfusion processes could be a major improvement area for biologic manufacturers.
PAP-Q2-17-RT-001 -
Q: How is Growth in the Biosimilars Market Impacting the Development of New Biologics Manufacturing Equipment Technologies?
Biosimilar market growth is heightening the pressure to improve cost and quality.
PAP-Q2-17-RT-003 -
Q: Has Downstream Processing Technology Caught up with the Significantly Higher Titers Coming Out of the Current Upstream Process? If No, What Issues Remain?
Yes, downstream technology development is advancing to accommodate higher titers via multiple chromatography approaches.
PAP-Q2-17-RT-004 -
Q: What is the Most Significant Recent Advancement in Downstream Bioprocessing Technology? Why is it so Important?
Recent advancements in continuous chromatography and SPTFF are all contributing to significant improvements across the complete process.
PAP-Q2-17-RT-002
-
The People’s Choice: Premeasured Single Dosage Forms
David Kudla, General Manager for North America and Rao Tatapudy, R.Ph., Ph.D., Executive Director, Research & Development for Unither Pharmaceuticals, discuss unit dosing and patient compliance.
-
A Culture of Innovation in Southeast England
Sarah Haywood, the CEO for MedCity, explains the organization.
-
LabCorp Makes Another Acquisition
LabCorp purchases UK-based contract research organization Chiltern for $1.2 billion.
-
Genetic Analysis of Solid Tumors Provides Insight on How They Spread
New gene sequencing technique developed by University of Michigan researchers reveals that metastasized tumors have many more mutations.
-
Avara on the Road to BIO: Taking Direction From Industry Veterans
Bill Pasek, Executive Vice President & Chief Commercial Officer for Avara Pharmaceutical Services explains honoring commitments.
-
Serialization: The First Steps In Sales Unit Traceability and Data Management
Michael Kinsella, Projects Director Serialization & Packaging, Supply Chain at Servier CDMO explores the impact of serialization.
-
Academic-Industry Partnership Receives Funds to Develop Ebola Vaccine
Integrated BioTherapeutics and The Scripps Research Institute awarded $6.6 million to develop a vaccine that protects against all ebola viruses.
-
Study Projects an $18 billion Neuroprosthetics Market by 2028
Vision and hearing both have a stake in the coming wave of innovation.
-
Nice Insight Overview: The Key to Pharma’s Next Generation Success
Evolving markets are prompting drug owners and developers to pursue new business models in the post-blockbuster era.
-
Process Optimization: Innovation's Role
Process optimization is a key service for the drug development industry that supports innovation and efficiency.
MOST VIEWED THIS MONTH
The Road To BIO: An Epic Jouney
View All
Pharma's Almanac TV
View All VideoThe Advantage of Having a Drug Development Company Behind Manufacturing
Stephen Worsley, Vice President, Business Development, Peregrine Pharmaceuticals & Avid Bioservices, Inc.
Emphasis on Aggressive Cancer Cells
Richard Godfrey, CEO, BerGenBio ASA
Finding the Sweet Spot With Biosimilars and mAbs
Federico Pollano, Director, Polpharma Biologics
Inside Out: Targeting Proteins on Cancer Cells
Mahesh Narayanan, President & CEO, PepVax, Inc.
Latest
View All LatestAn Existing Diabetes Drug Could Help Patients with Parkinson’s Disease
Aug 17, 2017 4:13:04 PM PAO-M08-17-NI-025Mallinckrodt Acquires InfaCare Pharmaceutical Corporation for $425 Million
Aug 17, 2017 3:54:12 PM PAO-M08-17-NI-023Study Projects an $18 Billion Neuroprosthetics Market by 2028
Aug 15, 2017 1:09:01 PM PAO-M08-17-NI-022Academic-Industry Partnership Receives Funds to Develop Ebola Vaccine
Aug 15, 2017 12:14:38 PM PAO-M08-17-NI-021Genetic Analysis of Solid Tumors Provides Insight on How They Spread
Aug 15, 2017 11:57:35 AM PAO-M08-17-NI-020Kite Submits Investigational New Drug Application for KITE-585
Aug 11, 2017 3:28:25 PM PAO-M08-17-NI-018Brains On-Line Acquired by Charles River Laboratories for $21 million
Aug 11, 2017 3:25:43 PM PAO-M08-17-NI-017Cambrex Invests in New Highly Potent API Manufacturing Capacity
Aug 11, 2017 3:22:34 PM PAO-M08-17-NI-016Bristol-Myers Squibb Will Acquire IFM Therapeutics’ Innate Immune System Stimulators
Aug 11, 2017 3:01:56 PM PAO-M08-17-NI-015Collaboration Targets Vaccine Technologies to Wipe out HIV-1 and Hep-B
Aug 8, 2017 11:48:52 AM PAO-M08-17-NI-013CMC and Trellis Agree to Develop mAb Therapies to Treat Viral, Bacterial Infections
Aug 4, 2017 1:47:28 PM PAO-M08-17-NI-010Harvard Researchers Develop a New Adhesive That Adheres Even to Wet Wounds
Aug 4, 2017 1:41:58 PM PAO-M08-17-NI-009WuXi Passes Pre-License Inspection for mAb-Based HIV Treatment Production
Aug 4, 2017 1:35:43 PM PAO-M08-17-NI-008Boehringer Ingelheim Expands Biologics Manufacturing Capacity in California
Aug 4, 2017 1:11:28 PM PAO-M08-17-NI-007New Drug Approved to Prevent Hereditary Angioedema Attacks Now Available in the US
Aug 4, 2017 1:06:44 PM PAO-M08-17-NI-006Michael J. Fox Foundation and CASIS Partner to Grow Parkinson’s Protein in Space
Aug 1, 2017 12:45:27 PM PAO-M08-17-NI-005Joint Program Explores Devices to Treat Gastrointestinal Disease
Aug 1, 2017 12:40:00 PM PAO-M08-17-NI-004Lonza Pharm&Biotech Constructing Manufacturing Complex in Switzerland
Aug 1, 2017 12:35:46 PM PAO-M08-17-NI-003Press Release
View All PRTopics
View All Topics
Building a One-Stop Shop CDMO for Biopharmaceuticals
PAP-Q2-17-CL-012
Designing Flexibility for Added Value
PAP-Q2-17-CL-015
The People’s Choice: Premeasured Single Dosage Forms
PAP-Q2-17-CL-014
Columns
Making Real-Time Process Analytical Technology In Biomanufacturing a Reality
